These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36181289)

  • 1. A miR-15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum-based chemotherapy.
    Xue P; Zhang G; Zhang H; Cui S; Zhang L; Yu T; Xiao M; Li L; Lu X
    J Cell Mol Med; 2022 Nov; 26(21):5439-5451. PubMed ID: 36181289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression.
    Yu T; Xue P; Cui S; Zhang L; Zhang G; Xiao M; Zheng X; Zhang Q; Cai Y; Jin C; Yang J; Wu S; Lu X
    Cancer Med; 2018 Dec; 7(12):6317-6330. PubMed ID: 30453383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
    Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL
    Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
    Gao H; Ge RC; Liu HY; Wang Y; Yan S
    Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
    Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
    Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
    Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
    J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study.
    Zhang Q; Zheng X; Li X; Sun D; Xue P; Zhang G; Xiao M; Cai Y; Jin C; Yang J; Wu S; Lu X
    Cancer Med; 2018 Apr; 7(4):1264-1274. PubMed ID: 29516665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.